Inflexion

Rosemont Pharmaceuticals

In June 2020 Inflexion acquired Rosemont Pharmaceuticals, the UK’s leading liquid pharmaceuticals business. The business was carved out from US listed company, Perrigo.

  • Sector

    Healthcare and education

  • Headquarters

    Leeds, UK

  • Fund

    Buyout

  • Investment date

    June 2020

  • Status

    Current

The company

Rosemont Pharmaceuticals is the UK’s leading liquid pharmaceuticals business. Its portfolio of over 130 oral liquid medicines includes 70 licensed products which are sold into the UK as well as the US, Continental Europe and the Middle East. The business benefits from strong R&D and innovation, and has built a track record of successful new product launches.

The Inflexion difference

With substantial experience in successfully executing carve-outs, Inflexion will draw upon its healthcare expertise to establish Rosemont as a standalone business and invest further in innovation and new product development. Inflexion will also support the geographical expansion of the business.